These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 11640868

  • 21. A detailed physical and transcriptional map of the region of chromosome 20 that is deleted in myeloproliferative disorders and refinement of the common deleted region.
    Bench AJ, Aldred MA, Humphray SJ, Champion KM, Gilbert JG, Asimakopoulos FA, Deloukas P, Gwilliam R, Bentley DR, Green AR.
    Genomics; 1998 May 01; 49(3):351-62. PubMed ID: 9615219
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. A myeloproliferative disorder may hide another one.
    Laibe S, Tadrist Z, Arnoulet C, Sainty D, Mozziconacci MJ.
    Leuk Res; 2009 Aug 01; 33(8):1133-6. PubMed ID: 19250672
    [Abstract] [Full Text] [Related]

  • 24. Trends in the incidence of chronic Philadelphia chromosome negative (Ph-) myeloproliferative disorders in the city of Göteborg, Sweden, during 1983-99.
    Johansson P, Kutti J, Andréasson B, Safai-Kutti S, Vilén L, Wedel H, Ridell B.
    J Intern Med; 2004 Aug 01; 256(2):161-5. PubMed ID: 15257729
    [Abstract] [Full Text] [Related]

  • 25. Prognostic significance of del(20q) in patients with hematological malignancies.
    Brezinová J, Zemanová Z, Ransdorfová S, Sindelárová L, Sisková M, Neuwirtová R, Cermák J, Michalová K.
    Cancer Genet Cytogenet; 2005 Jul 15; 160(2):188-92. PubMed ID: 15993278
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Chromosome abnormalities in the myeloproliferative disorders.
    Dewald GW, Wright PI.
    Semin Oncol; 1995 Aug 15; 22(4):341-54. PubMed ID: 7638632
    [No Abstract] [Full Text] [Related]

  • 28. Bone morphogenetic protein antagonist gene NOG is involved in myeloproliferative disease associated with myelofibrosis.
    Andrieux J, Roche-Lestienne C, Geffroy S, Desterke C, Grardel N, Plantier I, Selleslag D, Demory JL, Laï JL, Leleu X, Le Bousse-Kerdiles C, Vandenberghe P.
    Cancer Genet Cytogenet; 2007 Oct 01; 178(1):11-6. PubMed ID: 17889703
    [Abstract] [Full Text] [Related]

  • 29. The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders.
    Larsen TS, Christensen JH, Hasselbalch HC, Pallisgaard N.
    Br J Haematol; 2007 Mar 01; 136(5):745-51. PubMed ID: 17313377
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Oncogenic signals as treatment targets in classic myeloproliferative neoplasms.
    Tefferi A, Levine RL, Kantarjian H.
    Biol Blood Marrow Transplant; 2009 Jan 01; 15(1 Suppl):114-9. PubMed ID: 19147089
    [Abstract] [Full Text] [Related]

  • 32. Cryptic and partial deletions of PRDM16 and RUNX1 without t(1;21)(p36;q22) and/or RUNX1-PRDM16 fusion in a case of progressive chronic myeloid leukemia: a complex chromosomal rearrangement of underestimated frequency in disease progression?
    Deluche L, Joha S, Corm S, Daudignon A, Geffroy S, Quief S, Villenet C, Kerckaert JP, Laï JL, Preudhomme C, Roche-Lestienne C.
    Genes Chromosomes Cancer; 2008 Dec 01; 47(12):1110-7. PubMed ID: 18767145
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies.
    Giagounidis AA, Germing U, Aul C.
    Clin Cancer Res; 2006 Jan 01; 12(1):5-10. PubMed ID: 16397017
    [Abstract] [Full Text] [Related]

  • 35. Conventional cytogenetics of myeloproliferative diseases other than CML contribute valid information.
    Bacher U, Haferlach T, Kern W, Hiddemann W, Schnittger S, Schoch C.
    Ann Hematol; 2005 Apr 01; 84(4):250-7. PubMed ID: 15692838
    [Abstract] [Full Text] [Related]

  • 36. Molecular Pathogenesis of MDS.
    Look AT.
    Hematology Am Soc Hematol Educ Program; 2005 Apr 01; ():156-60. PubMed ID: 16304374
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Cytogenetic evolution in myeloproliferative neoplasms with different molecular abnormalities.
    Kim SY, Koo M, Park Y, Kim H, Choi Q, Song IC, Jo DY, Kim J, Kwon GC, Koo SH.
    Blood Cells Mol Dis; 2019 Jul 01; 77():120-128. PubMed ID: 31059941
    [Abstract] [Full Text] [Related]

  • 39. AML transformation in 56 patients with Ph- MPD in two well defined populations.
    Abdulkarim K, Girodon F, Johansson P, Maynadié M, Kutti J, Carli PM, Bovet E, Andréasson B.
    Eur J Haematol; 2009 Feb 01; 82(2):106-11. PubMed ID: 19134023
    [Abstract] [Full Text] [Related]

  • 40. Philadelphia chromosome-negative chronic myeloproliferative disease.
    Thiele J.
    Am J Clin Pathol; 2009 Aug 01; 132(2):261-80. PubMed ID: 19605821
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.